Surgery is a Common Treatment for Lung Cancer
While your surgeon will use every means possible to identify and remove your cancer, some cancer may be difficult to find during surgery.
CYTALUX® is the only FDA approved fluorescent imaging technology to light up lung cancer during surgery — enhancing your surgeon’s ability to visualize cancer in real time.
Clinically Proven
In a clinical trial, CYTALUX was proven to
help surgeons better visualize lung cancer.
19% of patients had lesions that their surgeon could not detect without the use of CYTALUX.
In 8% of patients, surgeons found one or more additional cancerous lesions that were not previously identified.
*In the clinical trial, a close resection margin was defined as follows: the rim of healthy tissue surrounding the lesion that was removed (also known as the margin) was ≤ 10 mm.
How CYTALUX Works
Given Before Surgery
CYTALUX is given to patients with lung cancer intravenously 1-24 hours prior to surgery. It circulates through the body, binding to and “lighting up” lung cancer cells when used with a special surgical camera. This allows the surgeon to more easily see the cancerous tissue (via a surgical camera) as they operate.
Safety Profile
The most common side effects of CYTALUX reported in clinical trials were nausea (13%), vomiting (5%), abdominal pain (2%), flushing (2%), other infusion-related reactions (2%), allergic reaction (2%), elevation in blood pressure (1%), indigestion (1%), and chest discomfort (1%) during administration.
During the Phase 3 clinical study, there were zero serious drug-related adverse events reported, and 92% of drug-related adverse events were mild or moderate.
You’re Not Alone in Your Journey.
Learn about some lung cancer support groups and resources that can help you along the way.
Stories and support